Fusion protein and derivative thereof, and use thereof in traumatic or perioperative hemostasis
By designing a fusion protein targeting TLT-1, and combining it with the extracellular domain of tissue factor and nanobodies, the non-targeting and stability issues of existing hemostatic drugs have been resolved, providing a stable liquid hemostatic agent at room temperature, thus achieving safe and efficient hemostasis for trauma and perioperative periods.
Patent Information
- Application Number
- PCT/CN2025/145728
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-07
- Filing Date
- 2025-12-25
- Publication Date
- 2026-11-12
AI Technical Summary
Existing hemostatic drugs, such as recombinant human thrombin, are non-targeting, have poor stability, are costly, and are limited in use in resource-constrained medical environments, making it difficult to provide an effective and safe hemostatic solution for trauma and the perioperative period.
A fusion protein was developed, comprising the extracellular domain of tissue factor, an anti-TLT-1 single-domain antibody, and a linker peptide. By targeting and activating the TLT-1 receptor on the platelet surface, it promotes local coagulation and avoids systemic thrombotic side effects. The combination of nanobodies and linker peptides ensures long-term stability at room temperature.
This invention achieves long-term stability of the liquid formulation at room temperature, has wide applicability, significantly improves hemostatic effect, avoids the risk of systemic thrombosis, and is suitable for hemostasis in trauma and perioperative period.
Smart Images

Figure CN2025145728_12112026_PF_FP_ABST
Abstract
Description
Fusion proteins and their derivatives and their application in hemostasis during trauma or perioperative period
[0001] This invention claims priority to Chinese Patent Application No. CN2025105816264, filed on May 7, 2025, entitled "Fusion Protein and its Derivatives and their Use in Hemostasis of Traumatic or Perioperative Period", the entire contents of which are incorporated herein by reference. Technical Field
[0002] This invention belongs to the field of protein engineering and relates to tissue factor fusion proteins, specifically to a fusion protein and its derivatives and their application in hemostasis during trauma or perioperative period. Background Technology
[0003] Tissue factor (TF), also known as coagulation factor iii, is a transmembrane glycoprotein primarily found in fibroblasts and smooth muscle cells of extravascular tissues. Under normal circumstances, it does not directly contact the blood. When blood vessels are damaged, TF is exposed to the blood and binds to coagulation factor VII (FVII), accelerating the coagulation process and acting as a key factor in initiating the extrinsic coagulation pathway. The TF-FVIIa complex not only initiates the extrinsic coagulation pathway but also activates the intrinsic coagulation pathway. The TF-FVIIa complex can activate coagulation factor IX (FIX), converting it to FIXa. FIXa binds to coagulation factor VII (FVII) to form a complex, further activating FIX. Thus, the TF-FVIIa complex, by activating FIX and FIX, connects the extrinsic and intrinsic coagulation pathways, forming a complete coagulation cascade. TF also plays an important role in the formation and stability of blood clots. The TF-FVIIa complex, by activating FIX and FIX, promotes fibrin formation and cross-linking, enhancing the stability of blood clots. Furthermore, TFs can regulate platelet activation and aggregation, further promoting clot formation. Neither full-length TFs nor their soluble extracellular domains (sTFs) can be used alone as therapeutic molecules. This is because, on the one hand, the membrane protein domains of full-length TFs can nonspecifically adhere to any part of the body, activating the coagulation system and leading to extensive disseminated thrombosis, a phenomenon noted in the early 20th century (Howell, 1912, Am. J. Physiol., Vol. 31, p. 121). On the other hand, sTFs are several orders of magnitude less potent than their full-length counterparts: this is because sTFs lacking membrane protein regions (membrane anchoring) cannot form effective on-membrane conformations with FVIIa to support / enhance the full proteolytic activity of FVIIa (Paborsky, 1991; Petrilo, 2010), rendering sTFs essentially nonfunctional, especially at lower doses (Morrissey, U.S. Patent 5,504,067). Therefore, anchoring sTF to the cell surface and maintaining the normal three-dimensional conformation after binding with FVIIa is key to the function of sTF.
[0004] Platelets play a crucial role in hemostasis, responding rapidly to vascular injury through various mechanisms such as adhesion, aggregation, release responses, and contraction to form platelet plugs and fibrin networks, effectively preventing blood loss. Triggering receptor expression on myeloid cells-like transcription 1 (TLT-1) is a molecule primarily expressed on the surface of activated platelets, with high expression only occurring when platelets are activated. Studies have shown that TLT-1 plays a key role in platelet activation. It not only participates in platelet aggregation and adhesion but also regulates platelet signaling through interactions with various cytokines and receptors. High TLT-1 expression is closely related to platelet activation status, with significantly higher expression levels on the surface of activated platelets than on resting platelets. Therefore, strategies targeting TLT-1 have potential applications in hemostasis. By designing antibodies or fusion proteins that can specifically bind to TLT-1 without affecting its normal function, drugs can be precisely delivered to the surface of activated platelets, thereby enhancing hemostasis.
[0005] Currently, local bleeding from trauma and surgery can be mainly divided into intraoperative bleeding and postoperative oozing, each requiring different hemostatic measures to achieve hemostasis and minimize patient bleeding. Existing surgical hemostasis techniques include mechanical hemostasis methods such as suturing, electrocoagulation, and packing, and pharmacological hemostasis methods such as thrombin and snake venom thrombin. Pharmacological hemostasis is mainly divided into four categories: drugs that reduce capillary permeability, drugs that activate coagulation factors, antifibrinolytic drugs, and other hemostatic drugs. Among these, recombinant human thrombin drugs for local administration in surgical hemostasis include Recothrom (approved by the FDA in 2008) and recombinant human thrombin (approved by the NMPA in 2024). Due to their coagulation mechanism and non-targeted nature, these drugs carry higher safety risks and require strict control of dosage and duration of use; otherwise, adverse reactions such as systemic thrombosis may occur. Although recombinant human thrombin is produced through gene recombination technology, reducing the immunogenicity of animal-derived thrombin, a small number of patients may still develop antibodies, affecting the long-term efficacy of the drug. Furthermore, recombinant human thrombin is relatively expensive, and the final formulations of this type of drug are all lyophilized powder injections that require cold chain storage and transportation at 2-8°C and need to be reconstituted before administration, limiting their widespread application in some resource-constrained medical environments. Therefore, to address the aforementioned unmet clinical needs, there is an urgent need to develop new drugs for trauma and perioperative hemostasis that offer advantages such as targeted hemostasis, long-term stability at room temperature, and liquid formulations, to ensure that patients receive effective and safe treatment in various environments. Summary of the Invention
[0006] This invention addresses the issues of low stability and non-targeted hemostasis in existing technologies by providing a fusion protein and its derivatives for hemostasis in trauma or perioperative periods. The invention provides a fusion protein composed of a nanobody (VHH) against the TLT-1 receptor molecule and the extracellular (soluble) domain (sTF) of tissue factor. TLT-1, also known as the trigger receptor, is present in the α-granules of resting platelets. However, during local bleeding or thrombosis, changes in blood shear stress at the lesion site and exposure of molecules such as VWF / collagen under the endothelium can activate platelets, causing TLT-1 to translocate from the α-granules to the platelet surface. Numerous studies have shown that TLT-1 is expressed only on the surface of activated platelets; based on this specificity, the TLT-1 receptor molecule is particularly suitable as a target for macromolecular drugs. The sTF-TLT-1 fusion protein developed based on this mechanism can guide sTF to the platelet surface at the bleeding site, forming a complex with endogenous FVII / FVIIa at the bleeding site, thereby promoting local hemostasis. Targeted hemostasis avoids the systemic thrombosis side effects caused by random hemostatic agents (snake venom, thrombin) compared to random hemostatic agents.
[0007] The fusion protein provided by the present invention comprises the following components: (i) the extracellular domain of tissue factor protein, (ii) an anti-TLT-1 single-domain antibody and (iii) a linker peptide; the number of the anti-TLT-1 single-domain antibody is one or more; the anti-TLT-1 single-domain antibody is located at the N-terminus or C-terminus of the extracellular domain of the tissue factor protein; the linker peptide is used for linking (i) and (ii).
[0008] To achieve the above objectives, the technical solution adopted by the present invention is as follows:
[0009] On one hand, the present invention provides a fusion protein for promoting coagulation, the fusion protein comprising the following components: (i) the extracellular domain of tissue factor protein, (ii) an anti-TLT-1 single-domain antibody and (iii) a linker peptide; the number of the anti-TLT-1 single-domain antibody is one or more; the anti-TLT-1 single-domain antibody is located at the N-terminus or C-terminus of the extracellular domain of the tissue factor; the linker peptide is used for linking (i) and (ii).
[0010] Preferably, the extracellular domain of the tissue factor protein has the amino acid sequence shown in SEQ ID NO.2; the anti-TLT-1 single-domain antibody includes any one of the amino acid sequences shown in SEQ ID NO.3-5, or an amino acid sequence having at least 95% homology with the framework region of the nanobody shown in any one of the amino acid sequences shown in SEQ ID NO.3-5.
[0011] Preferably, the linker peptide is 15-30 amino acids in length, and the amino acid sequence of the linker peptide includes the amino acid sequence shown in SEQ ID NO. 6 or 7.
[0012] Preferably, the structure of the fusion protein is selected from any combination of the following:
[0013] Combination 1: (i)-(iii)-(ii)-(iii)-(ii);
[0014] Combination 2: (ii)-(iii)-(ii)-(iii)-(i);
[0015] Combination 3: (ii)-(iii)-(i).
[0016] Preferably, when the fusion protein structure is selected from combination 1, it includes the amino acid sequence shown in any one of SEQ ID NO. 25, 30, 32 and 33; when the fusion protein structure is selected from combination 2, it includes the amino acid sequence shown in any one of SEQ ID NO. 26, 28, 31, 34 and 35; when the fusion protein structure is selected from combination 3, it includes the amino acid sequence shown in SEQ ID NO. 38.
[0017] Preferably, the C-terminus of the fusion protein is also linked to a histidine tag.
[0018] On the other hand, the present invention provides a genetically engineered product selected from any one or more of the following:
[0019] 1) A nucleic acid encoding the aforementioned fusion protein;
[0020] 2) An expression vector, wherein the expression vector comprises the nucleic acid described in 1);
[0021] 3) A genetically engineered cell, wherein the genetically engineered cell contains the nucleic acid described in 1), the expression vector described in 2), or expresses the above-mentioned fusion protein; the genetically engineered cell includes prokaryotic cells or eukaryotic cells.
[0022] On the other hand, the present invention provides the application of the above-mentioned fusion protein or the above-mentioned genetically engineered product in the preparation of hemostatic products for trauma or perioperative period.
[0023] On the other hand, the present invention provides a product for hemostasis in trauma or perioperative period, selected from any one or more of the following:
[0024] A. The product described herein includes the aforementioned fusion protein;
[0025] B. The product is prepared using the aforementioned genetically engineered product.
[0026] Preferably, the product is a pharmaceutical composition comprising a pharmaceutically acceptable formulation and pharmaceutical excipients, wherein the pharmaceutical excipients are selected from any one or more of topical sprays, syringes, creams, and gelatin sponges; and the product is selected from any one of solutions, suspensions, powders, and gels.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] 1. The fusion protein in this invention can bind tightly and specifically to TLT-1 molecules on activated platelets via nanobodies, thereby forming a three-dimensional conformation of sTF on the platelet surface similar to that of full-length TF. This conformation promotes the interaction between sTF and FVII, leading to the activation of a large number of FVII molecules and further promoting the downstream coagulation cascade reaction, producing a large amount of thrombin, thus achieving local rapid hemostasis. This fusion protein, while maintaining TLT-1 affinity activity, significantly enhances its procoagulant ability and can be applied to the preparation of hemostatic products for trauma or perioperative periods.
[0029] 2. The fusion protein in this invention selectively inserts a six-histidine His tag at its C-terminus to facilitate purification and detection.
[0030] 3. The fusion protein in this invention can maintain long-term stability in liquid form at room temperature in existing solution formulations. Compared with existing hemostatic drugs (snake venom, thrombin), it has significant advantages such as simple preparation, convenient carrying, and wide range of applications. Attached Figure Description
[0031] Figure 1 shows the binding curve of the recombinant fusion protein to the extracellular domain of the TLT-1 receptor (sTLT-1).
[0032] Figure 2 shows the binding curve of the recombinant fusion protein to activated human coagulation factor VII (FVIIa).
[0033] Figure 3 shows the binding curves of the recombinant fusion protein to both the extracellular domain of the human TLT-1 receptor (sTLT-1) and activated human coagulation factor VII (FVIIa).
[0034] Figure 4 shows the binding activity of the recombinant fusion protein with hTLT-1 expression cell lines.
[0035] Figure 5 shows the binding activity of the recombinant fusion protein with mTLT-1 expression cell lines.
[0036] Figure 6 shows the interaction curve between the recombinant fusion protein and FVIIa (amide degradation activity).
[0037] Figure 7 shows the interaction curves between the recombinant fusion protein and the extracellular region of TLT-1 and FVIIa (amide degradation activity).
[0038] Figure 8 shows the efficacy of the recombinant fusion protein in a rat liver hemorrhage model of topical hemostasis; where, compared with the model group, * represents p<0.05, *** represents p<0.001, and **** represents p<0.0001; compared with the Thrombin group, ### represents p<0.001, and #### represents p<0.0001. Detailed Implementation
[0039] First, the relevant content involved in this aspect will be explained as follows:
[0040] A "single-domain antibody" (sdAb) or "heavy chain antibody heavy chain variable region" (VHH), also known as a nanobody, is an antibody fragment (12-15 kDa) composed of a monomeric variable antibody, i.e., the variable region of the antibody heavy chain. Single-domain antibodies are typically derived from camels. VHH and sdAb are used interchangeably in this patent. The amino acid sequence and structure of a single-domain antibody can be considered to consist of four frame regions or "FRs," referred to in the art as "Frame Region 1" or "FR1"; "Frame Region 2" or "FR2"; "Frame Region 3" or "FR3"; and "Frame Region 4" or "FR4," respectively; the frame regions are separated by three complementarity-determining regions or "CDRs," referred to in the art as "Complementarity-determining Region 1" or "CDR1"; "Complementarity-determining Region 2" or "CDR2"; and "Complementarity-determining Region 3" or "CDR3," respectively. Therefore, a single-domain antibody can be defined as having the following general amino acid sequence: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4, where FR1-FR4 refer to framework regions 1-4, and CDR1-CDR3 refer to complementarity-determining regions 1-3. In the context of this disclosure, the amino acid residues of a single-domain antibody are numbered according to the general numbering method for the VH domain given by the International ImMunoGeneTics information system (http: / / imgt.cmes.fr / ).
[0041] As used herein, the terms "Fc" or "Fc region," "Fc domain," or "Fc fragment" refer to polypeptides composed of the CH2 and CH3 domains of IgA, IgD, and IgG, or the CH2, CH3, and CH4 domains of IgE and IgM via a hinge region. Although the breakdown of Fc fragments is variable, the Fc fragment of the heavy chain of human IgG typically refers to the polypeptide segment from A231 to its carboxyl terminus.
[0042] Tissue factor (TF), also known as F3 or CD142, is a membrane-bound protein encoded by the F3 gene, found in subendothelial tissues and leukocytes. Its role in the coagulation process is to initiate an extrinsic cascade reaction, promoting coagulation. The extracellular domain (sTF) of tissue factor refers to the TF protein lacking both the membrane protein domain and the intracellular domain. In the fusion protein of this invention, the extracellular domain of tissue factor (sTF) is selected from amino acid residues 1-208 to 1-221 or 1-209 to 1-220 of SEQ ID NO.1; preferably, the extracellular domain sequence of tissue factor (sTF) is SEQ ID NO.2.
[0043] “TREM (Trigger Receptor Expressed on Bone Marrow Cells) Transcript-1” (TLT-1), as used herein, is a membrane protein receptor found only in the α-granules of platelets and megakaryocytes. TLT-1 contains an extracellular type V Ig-like domain, a proline-rich region, and an immunoreceptor tyrosine repressive motif in a cytoplasmic tail region. Upon platelet activation, TLT-1 rapidly reaches the platelet surface and enhances Ca++ influx and promotes platelet aggregation. The TLT-1 protein surface contains numerous grooves (Gattis et al., 2006, Proc. Natl. Acad. Sci. USA, Vol. 281, pp. 13396–13403). The article suggests that these grooves make TLT-1 particularly well-suited for interaction with single-domain antibodies. These surface grooves appear to contain amino acid residues with both negatively and uncharged electrostatic properties, which can interact with selected amino acids explicitly and conformally shown on the sdAb.
[0044] This invention relates to a high-affinity single-domain antibody (VHH) that specifically binds to the TLT-1 receptor on the surface of activated mouse or human platelets. Due to its small molecular weight, high stability, numerous usable epitopes, and relatively low production cost, VHH is chosen as the targeting agent for preparing fusion proteins. This invention also relates to fusion proteins containing the extracellular (soluble) domain of tissue factor (sTF) linked to these single-domain antibodies, for effectively targeting sTF to vascular injury sites. The targeting effect is achieved through the binding of VHH to TLT-1, a membrane protein receptor whose expression is limited to the α-granules of resting platelets and megakaryocytes, and then translocates to the platelet surface after platelet activation. This targeting effect allows sTF to maintain its normal three-dimensional conformation on the cell surface, maximizing the activation of FVII and exerting a strong hemostatic function. Simultaneously, it minimizes the chance of disseminated intravascular coagulation (DIC) induced by non-targeted thrombin generation.
[0045] The present invention relates to a fusion protein comprising (a) an extracellular domain of a tissue factor, (b) a single-domain antibody against TLT-1, and (c) a linker peptide.
[0046] This invention relates to activated platelets. Activated platelets are substrates for numerous components of the coagulation cascade and, upon binding to fibrinogen, can produce fibrin needed to close vascular damage. This invention fuses VHH with the soluble domain (sTF) of human tissue factor. By inserting the high-affinity VHH from the fusion protein into the relevant spatial epitope of the TLT-1 protein, the extracellular domain of TF is anchored to activated platelets. Based on this correct surface localization, the sTF domain is thermodynamically favorable for binding to FVII in the blood system and activating it in situ to FVIIa. FVIIa then sequentially activates FX to FXa, further stimulating and promoting the common coagulation cascade reaction.
[0047] As used herein, the term "affinity" or "binding affinity" refers to the intrinsic binding affinity that reflects the interaction between members of a binding pair. Affinity can be measured by common methods known in the art. One specific method used to measure affinity is the ForteBio kinetic binding determination described herein.
[0048] As used in this article, the term "expression vector" refers to a nucleic acid molecule capable of replicating and expressing a target gene when transformed, transfected, or transduced into host cells. Expression vectors contain one or more phenotypic selection markers and origins of replication to ensure the maintenance of the vector and to provide amplification within the host when needed.
[0049] The terms “cell” and “cell line” used herein are used interchangeably, and all such names include their descendants. The term “host cell” refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli, fungal cells such as yeast cells, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells, or human cells.
[0050] The term “EC50” used in this article refers to the concentration for 50% of maximal effect, that is, the concentration that can produce a 50% maximal effect.
[0051] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to embodiments. Unless otherwise specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. Numerous specific details are provided in the following detailed description to better illustrate the invention. The specific embodiments described herein are for illustrative purposes only and are not intended to constitute any limitation on the invention. Furthermore, descriptions of well-known structures and techniques are omitted in the following description to avoid unnecessarily obscuring the concept of the invention. Such structures and techniques have also been described in many publications.
[0052] Data Analysis: SPSS 23.0 was used for data statistics and analysis in this invention, and t-tests were used for significance analysis. P < 0.05 indicates a significant difference.
[0053] Preparation example: Sequence description and fusion protein design
[0054] (1) Sequence Description
[0055] 1.1 The amino acid sequence of the full-length human tissue factor protein is as follows: SEQ ID NO.1:
[0056] 1.2 The sequence of the extracellular domain sTF209 of the tissue factor protein is shown in SEQ ID NO.2 below:
[0057] 1.3 The sequence of the nanobody sdAb 233 targeting the extracellular region of hTLT-1 is shown in SEQ ID NO.3 below:
[0058] 1.4 The sequence of the nanobody sdAb290 targeting the extracellular region of hTLT-1 is shown in SEQ ID NO.4 below:
[0059] 1.5 The sequence of the nanobody sdAb 11983 targeting the extracellular regions of hTLT-1 and mTLT-1 is shown in SEQ ID NO.5 below:
[0060] 1.6 The linker peptide contains the natural amino acid sequence GSGGGTGGGSGGSGGGT GGGSG (SEQ ID NO.6) derived from human transthyretin protein, and the artificial sequence GGGGSGGGGSGGGGS (SEQ ID NO.7).
[0061] 1.7. sdAb 233-VH4 is a mutant of sdAb 233, with the sequence shown in SEQ ID NO.8 below:
[0062] 1.8. sdAb11983-H4 is a mutant of sdAb 11983, with the sequence SEQ ID NO.9.
[0063] sdAb 233-VH4 and sdAb11983-H4 are mutated nanobodies that do not bind to hTLT-1 or mTLT-1. The sTF209-sdAb1-sdAb2 fusion protein constructed using this sequence has no platelet activation targeting activity and serves as a non-targeting negative control in this invention. Table 1 shows the CDR region sequences of the nanobodies involved in this invention.
[0064] Table 1. CDR region sequence of nanobodies
[0065] (2) Sequence composition of sTF209-sdAb1-sdAb2 fusion protein
[0066] Table 2 shows the structure of the fusion protein designed based on the above sequence. In the protein structure, "-6His" represents the C-terminus of the fusion protein connected to 6 His, which serve as His tags.
[0067] Table 2. List of names and conformations of recombinant sTF209-sdAb1-sdAb2 fusion protein and control protein.
[0068] NX20-12 fusion protein: HX-1-sTF209-Linker-sdAb233-Linker-sdAb11983-6His, with the following amino acid sequence as SEQ ID NO.25:
[0069] NX20-24 fusion protein: HX-1-sdAb233-Linker-sdAb11983-Linker-sTF209-6His, with the following amino acid sequence as SEQ ID NO.26:
[0070] NX20-25 fusion protein: HX-1-sTF209-Linker-sdAb 233-VH4-Linker-sdAb11983-H4-6His, with the following amino acid sequence as SEQ ID NO.27:
[0071] NX20-37 fusion protein: HX1-sdAb11983-Linker-sdAb233-Linker-sTF209-6His, with the following amino acid sequence as SEQ ID NO.28:
[0072] NX20-38 fusion protein: HX1-sdAb11983-H4-Linker-sdAb233-VH4-Linker-sTF209-6His, with the following amino acid sequence as SEQ ID NO.29:
[0073] NX20-22 fusion protein: HX1-sTF209-Linker-sdAb233-Linker-sdAb233-6His, with the following amino acid sequence as SEQ ID NO.30:
[0074] NX20-23 fusion protein: HX1-sdAb233-Linker-sdAb233-Linker-sTF209-6His, with the following amino acid sequence as SEQ ID NO.31:
[0075] The NX20-32 fusion protein, HX1-sTF209-Linker-sdAb233-Linker-sdAb290-6His, has the following amino acid sequence as SEQ ID NO.32:
[0076] NX20-33 fusion protein: HX1-sTF209-Linker-sdAb290-Linker-sdAb233-6His, with the following amino acid sequence as SEQ ID NO.33:
[0077] NX20-34 fusion protein: HX1-sdAb233-Linker-sdAb290-Linker-sTF209-6His, with the following amino acid sequence as SEQ ID NO.34:
[0078] NX20-35 fusion protein: HX1-sdAb290-Linker-sdAb233-Linker-sTF209-6His, with the following amino acid sequence as SEQ ID NO.35:
[0079] NX20-6 fusion protein: HX1-sTF209-Linker-sdAb233-6His, with the following amino acid sequence as SEQ ID NO.36:
[0080] NX20-9 fusion protein: HX1-sTF209-Linker-sdAb233, amino acid sequence as shown in SEQ ID NO.37:
[0081] NX20-14 fusion protein: HX1-sdAb233-Linker-sTF209, with the following amino acid sequence as SEQ ID NO.38:
[0082] In addition to the sequences disclosed above, in the fusion proteins involved in the specific embodiments, the linking peptide between the extracellular domain sTF209 of the tissue factor protein and the nanobody is GSGGGTGGGSGGSGGGTGGGSG (SEQ ID NO. 6), and the linking peptide between the nanobodies is GGGGSGGGGSGGGGS (SEQ ID NO. 7). Considering that the sequences of other parts are known except for the linking peptides, all fusion proteins are linked in different parts according to the above rules, and the sequences of all fusion proteins under this rule are determined.
[0083] Example 1: Construction of recombinant fusion protein
[0084] This invention uses the eukaryotic expression vector HX1, which contains key elements such as CMV enhancer, CMV promoter, multiple cloning site, SV40 poly(A)signal, and AmpR antibiotic resistance gene, to construct the fusion protein expression vector described in Table 2. Polymerase (MCLAB, I-5) was used. TMPCR amplification was performed on sTF209, sdAb233 (or sdAb233-VH4), sdAb11983 (or sdAb11983-H4), and sdAb290 fragments using 2X Hi-Fi PCR Master Mix (Cat#: I5HM-OEM) and specific primer pairs, respectively. This introduced restriction enzyme sites, the linker portion required for ligation between sTF209 and sdAb or between two sdAbs, and the stop codon. Primers were then used to assemble the sTF209, sdAb233 (or sdAb233-VH4), sdAb11983 (or sdAb11983-H4), and sdAb290 fragments, obtaining sTF209 and sdAb fragments assembled in different sequences. A sequence encoding six histidine residues (His) was selectively added to the 3' end of the gene fragments to facilitate the purification of the recombinant fusion protein. The fragment was ligated into a eukaryotic expression vector digested with BsiWI and BstBI restriction endonucleases using Gibson ligase (Genesand, Uniclone One Step Seamless Cloning Kit, Cat#: SC612).
[0085] Example 2: Expression and preparation of recombinant fusion protein
[0086] Each constructed plasmid was transiently transfected into HEK293F suspension cell line to express the recombinant fusion protein. The cell density was adjusted to 1.2-1.4 × 10⁶ cells / year 24 hours before transfection. 6 Incubate 293F cells at a concentration of approximately 100 mL / mL in a shake flask overnight at 37°C, 125 rpm, and 5% CO2. On the day of transfection, take a small number of cells for cell counting; the density should be approximately 3.0–3.5 × 10⁻⁶ cells / mL. 6 Cells with a viability greater than 95% can be transiently transfected. The transient transfection system consists of 20 μg plasmid and 40 μL Y-20 transfection reagent per 20 mL of 293F cell culture. After thoroughly mixing the cells and reagent, immediately incubate at 37°C, 125 rpm, and 5% CO2 in a shaker. On the first day after transfection, 16-22 hours post-transfection, add 5% (v / v) of 293-ProFeed to the shake flask while gently shaking it. After adding, return the flask to the incubator, maintaining the same incubation conditions of 37°C, 125 rpm, and 5% CO2. On the third day after transfection, collect a small number of cells daily for counting. When the viability drops to approximately 80%, collect the sample. Centrifuge the cell culture medium at 8000 rpm for 30 min, filter the supernatant, and store at 4°C for purification or at -20°C for long-term storage.
[0087] The His-tagged fusion proteins described in Table 2 were purified using Ni affinity chromatography. The purification packing material was 1 ml of HiTrap smart Ni 6FF (purchased from Tiandi Renhe), and the equilibration buffer consisted of 20 mM PB, 0.15 M NaCl, pH 7.2, for 10 column volumes. After equilibration, the supernatant of the His-tagged recombinant fusion protein was briefly transferred, filtered, and loaded onto the sample. The mixture was then reequilibrated (the buffer system consisted of 98.8% (v / v) buffer A and 1.2% buffer B; buffer A consisted of 20 mM PB, 0.5 M NaCl, pH 7.4; buffer B consisted of 20 mM PB, 0.1 M NaCl, 0.5 M imidazole, pH 7.2) until UV stability was achieved, and then the baseline was leveled using buffer A. The elution buffer consisted of 20 mM PB, 0.1 M NaCl, 0-0.5 M imidazole, pH 7.2, and linear elution was used.
[0088] The fusion proteins without His tags (such as NX20-9 and NX20-14) listed in Table 2 were purified using cationic affinity chromatography. The purification packing material was HiTrap SP (purchased from Cytiva), and the equilibration buffer was 50 mM NaAc, pH 4.5. The supernatant was diluted with equilibration buffer, filtered, and loaded onto the plate, then equilibrated again for 20 column volumes. The elution buffer consisted of 50 mM NaAc, 0–0.5 M NaCl, pH 4.5, and linear elution was used.
[0089] The purified protein was centrifuged and concentrated at 3000-4000 rpm at 4°C using an appropriately sized ultrafiltration tube. The protein buffer was then replaced with PBS buffer (pH 7.4). Protein concentration was measured using NanoDrop (purchased from Thermo Fisher Scientific, USA), yielding the recombinant fusion protein, which was stored at -20°C. A small amount of protein was taken and its purity was characterized by SDS-PAGE. The results showed that the protein bands were single, with no other bands, and the purity was greater than 95%.
[0090] Example 3: Binding activity of recombinant fusion protein to the extracellular domain of TLT-1 receptor (sTLT-1)
[0091] The binding activities of the recombinant fusion protein to human sTLT-1 and FVIIa were detected by ELISA, with sTF209 and nanobodies serving as controls. Human sTLT-1-Fc was a self-prepared antigen, constructed by fusing an Fc tag to the C-terminus of the sTLT-1 protein. The protein was expressed using the transient transfection system described in Example 2, and the antigen was purified using Protein A packing material. Purification was performed using a PBS buffer system for elution and equilibration, with 50 mM NaAc as the elution buffer.
[0092] The day before the experiment, human sTLT-1-Fc protein was immobilized in 96-well plates and incubated overnight at 4°C. On the day of the experiment, the coated wells were blocked with PBS-T containing 2% BSA at room temperature for 2 hours. Serially diluted refusion protein and its control protein were added to the coated 96-well plates and incubated for 1 hour. After washing three times with PBS-T, HRP-labeled anti-His antibody was added, and the plates were incubated at room temperature for 1 hour. After incubation, the 96-well plates were washed at least three times with PBS-T, and 100 μL of TMB chromogenic buffer (Solepro) was added to each well. The reaction was carried out in the dark for 5-10 minutes, followed by the addition of 2M sulfuric acid to terminate the reaction. Absorbance was recorded at 450 nm and 630 nm using a multi-plate reader (BioTek), and OD values were analyzed. 450nm -OD 630nm (OD 450nm value minus OD 630nm The values (the same below) are used to plot a binding curve with the concentration of the protein to be tested, and the binding EC50 value is calculated.
[0093] Figure 1 shows the target binding activity curves of fusion proteins with different structures and their control proteins at different concentrations with human TLT-1-Fc. Table 3 shows the EC50 concentrations of the antibodies binding to the target, calculated based on the binding activity curves in Figure 1. In this embodiment, recombinant sTF209 fused with different nanobody fusion proteins at the C-terminus and N-terminus maintained target binding activity similar to sdAb233.
[0094] Table 3. EC50 values of recombinant fusion protein binding to the extracellular domain of TLT-1 receptor (sTLT-1) Note: N / A indicates no binding.
[0095] Example 4: Binding activity of recombinant fusion protein to activated human coagulation factor VII (FVIIa)
[0096] The binding activity of the recombinant fusion protein and its control to FVIIa was detected by ELISA. Anti-His-Tag antibody (purchased from ProteinTech, catalog number 66005-1-lg) was immobilized in 96-well plates and incubated overnight at 4°C. The coated wells were blocked for 2 hours at room temperature with buffer containing BSA and calcium ions. Serially diluted recombinant fusion protein and its control protein were added to the coated 96-well plates and incubated for 1 hour. After washing three times with PBS-T, FVIIa was added, and the plates were incubated for 1 hour at room temperature. After washing three times with PBS-T, diluted HRP-tagged Sheep Anti-Human Factor FVII was added, and the plates were incubated for another 1 hour. After incubation, the 96-well plates were washed at least three times with PBS-T, and 100 μL of TMB chromogenic solution (purchased from Solarbio) was added to each well. The plates were incubated in the dark for 3–10 minutes, followed by the addition of 2M sulfuric acid to terminate the reaction. Absorbance values were recorded at 450 nm and 630 nm using a multi-functional microplate reader (purchased from BioTek), and OD values were used. 450nm -OD 630nm Binding curves were plotted using the target protein concentrations, and the EC50 values were calculated. Figure 2 shows the binding activity curves of different fusion proteins and their control proteins at different concentrations with the target human TLT-1-Fc. Table 4 shows the calculated EC50 concentrations of the antibody binding to the target based on the binding activity curves in Figure 2. The results show that the recombinant fusion proteins with different structures have similar binding activities to FVIIa, with similar EC50 values, confirming that the C-terminus or N-terminus fusion nanobody of sTF209 does not affect the binding activity of sTF209 with FVIIa.
[0097] Table 4. EC50 values of recombinant fusion protein binding to activated human coagulation factor VII (FVIIa). Note: N / A indicates no binding.
[0098] Example 5: Binding activity of recombinant fusion protein to the extracellular domain of TLT-1 receptor (sTLT-1) and activated human coagulation factor VII (FVIIa).
[0099] The binding activities of the recombinant fusion protein and its control with sTLT-1 and FVIIa, respectively, were detected by ELISA. Human sTLT-1-Fc protein was immobilized in 96-well plates and incubated overnight at 4°C. The coated wells were blocked for 2 hours at room temperature with a buffer containing BSA and calcium ions. Serially diluted recombinant fusion protein and its control protein were added to the coated 96-well plates and incubated for 1 hour. After washing three times with PBS-T, FVIIa was added, and the plates were incubated for 1 hour at room temperature. After washing three times with PBS-T, diluted HRP-tagged Sheep Anti-Human Factor FVII was added, and the plates were incubated for another 1 hour. After incubation, the 96-well plates were washed at least three times with PBS-T, and 100 μL of TMB chromogenic solution (Solepro) was added to each well. The reaction was carried out in the dark for 3–10 minutes, followed by the addition of 2M sulfuric acid to terminate the reaction. The absorbance was recorded at 450 nm and 630 nm using a multi-mode microplate reader (BioTek), and the OD value was measured. 450nm -OD 630nm Binding curves were plotted using the target protein concentrations, and the EC50 values were calculated. Figure 3 shows the binding activity curves of different fusion proteins and their control proteins at different concentrations with the target of human sTLT-1-Fc. Table 5 shows the calculated EC50 concentrations of the antibody binding to the target based on the binding activity curves in Figure 5. The results show that the fusion proteins formed by fusing nanobodies with the C-terminus or N-terminus of sTF209 can simultaneously bind to both FVIIa and the extracellular domain of human TLT-1. Among them, NX20-24, NX20-37, NX20-23, NX20-34, and NX20-35 may bind more proteins, as evidenced by their higher EC50 and maximum absorbance (OD). 450nm -OD 630nm It is superior to other molecules.
[0100] Table 5. EC50 concentrations of the recombinant fusion protein that simultaneously bind to the extracellular domain of human TLT-1 receptor (sTLT-1) and activated human coagulation factor VII (FVIIa). Note: N / A indicates no simultaneous binding activity.
[0101] Example 6: Affinity (KD) Detection of Recombinant Fusion Protein with Human and Mouse TLT-1 Receptor Extracellular Domain (sTLT-1) and Activated Human Coagulation Factor VII (FVIIa)
[0102] This invention utilizes biolayer interferometry (BLI) to detect the affinity kinetics constants between recombinant fusion proteins and their targets. The Gator Pilot label-free molecular interaction analyzer was purchased from Gator Pilot, and all necessary consumables, including the Max Plate, BLI96-Flat Plate, ProG probe, and His probe, were purchased from Gator. When testing the affinity of the recombinant fusion protein for human sTLT-1 and mouse sTLT-1, the activated ProG probe was placed in the corresponding well of the Max Plate, and the prepared sTLT-1-Fc protein, recombinant fusion protein, and control sample were added to the corresponding wells of the BLI96-Flat Plate. Following the instrument's standard operating procedure, diluted sTLT-1 protein (5-10 μg / mL) was first immobilized onto the ProG probe, and then the binding and dissociation activities of the recombinant protein, serially diluted to 50, 25, and 12.5 nM, with sTLT-1 were detected. After the detection was completed, the binding rate (Kon), dissociation rate (Koff), and equilibrium dissociation constant (KD) were calculated using GatorOne Version 2.15.5.1221 software. Affinity information is shown in Tables 6 and 7. The results showed that, compared with sTF209-sdAb or single sdAb proteins, the sTF209-sdAb1-sdAb2 fusion protein, composed of two sdAbs tandemly at the C-terminus and N-terminus of sTF209, exhibited significantly increased affinity for the human and mouse sTLT-1 target, indicating that this structure can enrich activated platelets after binding to the specific receptor TLT-1 with high affinity. The highest affinity (KD) of the sTF209-sdAb1-sdAb2 fusion protein with human sTLT-1 reached E-012 (M), while the affinity with mouse sTLT-1 increased to E-008-E-010 (M).
[0103] When testing the affinity of the recombinant fusion protein for FVIIa, the activated His probe was placed in the corresponding well of the Max Plate, and the prepared FVIIa protein, fusion protein, and control sample were added to the corresponding wells of the BLI96-Flat Plate. Following the instrument's standard operating procedure, the fusion protein or corresponding control protein (5-10 μg / mL) was first immobilized onto the His probe, and then its binding and dissociation activities with FVIIa serially diluted to 200, 100, and 50 nM were measured. After the detection, the binding rate (Kon), dissociation rate (Koff), and equilibrium dissociation constant (KD) were calculated using GatorOne Version 2.15.5.1221 software. Affinity information is shown in Table 8. The results showed that, compared with sTF209-sdAb or sdAb protein alone, the sTF209-sdAb1-sdAb2 protein composed of two sdAbs tandemly at the C-terminus and N-terminus of sTF209 could still maintain its binding activity with FVIIa, and the affinity level (KD) remained at E-008-E-009(M).
[0104] Table 6. Affinity of recombinant fusion protein to human sTLT-1 Note: N / A indicates no binding activity.
[0105] Table 7. Affinity of recombinant fusion protein to mouse sTLT-1 Note: N / A indicates no binding activity.
[0106] Table 8. Affinity of recombinant fusion protein to FVIIa Note: N / A indicates no binding activity.
[0107] Example 7: Binding activity of recombinant fusion protein to cell lines expressing the extracellular domain of TLT-1 receptor (sTLT-1).
[0108] Stable cell lines (CHO-hTLT-1 and CHO-mTLT-1) in the logarithmic growth phase expressing high levels of human and mouse sTLT-1 were collected, mixed, and counted. Cell clusters were washed with 1×PBS buffer and centrifuged at 1000 rpm for 5 minutes. Cells were resuspended in 1×Cell staining buffer (BioLegend, catalog number 420201) and seeded in 96-well V-bottom culture plates (Beyotime Biotechnology, catalog number FPT019) at a density of 5×10⁶ cells per well. 5Cells / wells. Add 50 μL of serially diluted recombinant protein to each well to achieve final protein concentrations of 1000, 200, 40, 8, 1.6, 0.32, 0.064, and 0.0128 nM. Wells without antibody serve as negative controls. Incubate at 4°C for 1 hour. Wash cells twice with PBS, centrifuging at 250 × g for 5 minutes each time. Add 100 μL of secondary antibody diluted in PBS (His Tag Alexa). 488-conjugated antibody (purchased from R&D Systems, catalog number IC0501G, 0.1 μg / well) was added, and the cells were incubated at 4°C for 30 minutes. Cells were washed twice with PBS, centrifuged at 1000 rpm for 5 minutes each time. After washing, the cells were resuspended in PBS and incubated using BD Accurate... TM The average fluorescence intensity of the bispecific antibody was measured using a C6 flow cytometer (purchased from BD). Data processing was performed using Flowjo, and EC50 was calculated sequentially using Graphpad Prism fitting regions. This invention relates to the binding activity curves of recombinant fusion protein and corresponding controls at different concentrations with human and mouse TLT-1 receptor extracellular domain (sTLT-1) expression cell lines, as shown in Figures 4 and 5. EC50 results are shown in Table 9.
[0109] Table 9. EC50 values of the binding of the recombinant fusion protein to hTLT-1 and mTLT-1 expressing cell lines. Note: N / A indicates no binding activity.
[0110] Example 8: Simultaneous interaction of recombinant fusion protein with the extracellular domain of TLT-1 receptor (sTLT-1) and activated human coagulation factor VII (FVIIa)
[0111] The recombinant fusion protein involved in this invention aims to target and activate the platelet-specific antigen TLT-1 via nanobody sdAb, thereby delivering sTF to the surface of activated platelets. To verify whether the construction of the fusion protein affects the interaction between the sTF terminus and FVIIa, the amide degradation activity of FVIIa after the interaction of the fusion protein with FVIIa was first determined using an enzyme digestion substrate method. In a buffer containing calcium ions, the serially diluted fusion protein was mixed with equal volumes of FVIIa and incubated at room temperature for 20 minutes. After incubation, substrate S-2288 (purchased from Beijing Asrell) was added to the system to a final concentration of 0.5 mM, and the absorbance at 405 nm was measured using a microplate reader within 1 minute of reaction. The amide degradation activity curves of different fusion protein structures after interaction with FVIIa were plotted using Graphpad (Figure 6), and the EC50 value was calculated based on the absorbance readings after 5 hours (see Table 10). The results show that NX20-12, with two nanobody molecules fused to the C-terminus of the sTF209 protein, exhibits similar interactions with FVIIa as the control molecule sTF209 and the sTF209-sdAb fusion protein. After binding, its ability to promote the amide degradation activity of FVIIa is significantly superior to other sTF209-sdAb1-sdAb2 fusion protein structures. Therefore, different fusion methods of sTF209 and nanobodies may affect the interaction between sTF209 and FVIIa to some extent. Since the EC50 values of NX20-24, NX20-25, NX20-37, NX20-38, NX20-23, NX20-34, and NX20-35 differ from those of NX20-12, NX20-9, and NX20-14 by less than three times, this effect is considered small and may originate from steric hindrance or experimental errors caused by fusion.
[0112] To further verify the activity of the recombinant fusion protein in interacting with FVIIa after binding to the extracellular region of the TLT-1 receptor, the present invention first coated human sTLT-1-Fc protein overnight onto 96-well plates. After blocking with a buffer containing BSA and calcium ions at room temperature, serially diluted recombinant fusion protein and its control protein were added to the coated 96-well plates and incubated for 1 hour. After washing three times, FVIIa was added, and incubation was continued at room temperature for another hour. After incubation, substrate S-2288 was added to the system to a final concentration of 0.5 mM, and the absorbance at 405 nm was measured using a microplate reader within 1 min of the reaction. The amide degradation activity curves of different structural fusion proteins after interaction with FVIIa were plotted using Graphpad (Figure 7), and the EC50 value was calculated from the absorbance readings after 12 hours (see Table 11). The results showed that both sTF209-sdAb and sTF209-sdAb1-sdAb2 fusion proteins (excluding the non-target control molecule) could bind to the extracellular region of the TLT-1 receptor via the anti-TLT-1 nanobody terminus, while simultaneously binding FVIIa and promoting its amide degradation activity. Among them, the absorbance and EC50 values of the different fusion proteins with the sTF209-sdAb1-sdAb2 structure were superior to those of NX20-9 and NX20-14 with the sTF209-sdAb structure, confirming that the fusion of two nanobodies targeting the extracellular region of human sTLT-1 with sTF209 significantly enhances the binding ability to the target.
[0113] Table 10. EC50 values of the amide degradation activity of the recombinant fusion protein after interaction with FVIIa.
[0114] Table 11 EC50 values of the amide degradation activity of the recombinant fusion protein after binding to the extracellular region of TLT-1 and interacting with FVIIa. Note: N / A indicates no double-ended activity.
[0115] Example 9: Topical hemostatic efficacy of recombinant fusion protein in a rat liver hemorrhage model
[0116] This invention uses a rat liver hemorrhage model as a model for evaluating the procoagulant efficacy of recombinant fusion protein. The saline group served as a negative control, and thrombin (purchased from Solarbio) as a positive control. After weighing and anesthetizing the rats, enoxaparin (purchased from Sanofi) was injected via the tail vein to establish a heparinization model. A midline abdominal incision was made to expose the liver. The left lobe of the liver was located 2-5 mm from its outer edge and removed. The incision was covered with gelatin sponge thoroughly soaked in the drug before the experiment. Bleeding was observed every two minutes for 20 minutes. After 20 minutes, the filter paper and liver incision were photographed for recording. After hemostasis, the filter paper was replaced, and observation continued for another 20 minutes for re-bleeding. The total observation time was 40 minutes. Bleeding time was recorded, graphed using Graphpad, and one-way ANOVA was used to compare differences between groups.
[0117] There are differences in molecular weight among fusion proteins with different structures and control drugs. To better compare in vivo efficacy, this study used equimolar concentrations. The recombinant proteins NX20-12, NX20-24, NX20-25, NX20-37, NX20-38, NX20-22, NX20-23, NX20-32, NX20-33, NX20-34, and NX20-35 with the sTF209-sdAb1-sdAb2 structure were administered at a concentration of 0.07 mg / mL (molecular weight 52 kD), while the fusion proteins NX20-14 and NX20-9 with the sTF209-sdAb structure and the control thrombin were administered at a concentration of 0.05 mg / mL (molecular weight 37 kD). The in vivo efficacy results are shown in Table 12 and Figure 8. Compared with the model group, sTF209-sdAb and sTF209-sdAb1-sdAb2 showed clear topical hemostatic effects, with statistically significant differences in bleeding time. Among them, NX20-14, NX20-12, NX20-24, NX20-37, NX20-22, NX20-23, NX20-32, NX20-33, NX20-34, and NX20-35 significantly shortened bleeding time compared to the thrombin group, with statistically significant differences in bleeding time. Compared with the non-targeted fusion protein control groups NX20-25 and NX20-37, NX20-12, NX20-14, and NX20-37 significantly shortened bleeding time, demonstrating that targeted activation of platelets at the wound site can effectively improve hemostatic activity. Furthermore, based on mean values, some fusion proteins with the sTF209-sdAb1-sdAb2 structure, NX20-24, NX20-37, NX20-22, NX20-23, NX20-32, NX20-33, and NX20-34, exhibited superior procoagulant activity compared to NX20-9 and NX20-14 of the sTF209-sdAb structure, demonstrating shorter bleeding times. For sTF209-sdAb structural proteins, the NX20-14 molecule, obtained by fusing a TLT-1 nanobody to the N-terminus of sTF209, showed better efficacy than NX20-9, which was fused with a TLT-1 nanobody to the C-terminus.
[0118] Table 12 Effects of different drug groups on bleeding time
[0119] In summary, the sTF209 fusion with a platelet-targeting nanobody enhances the hemostatic efficacy of the recombinant protein. The fusion protein already exhibits clear procoagulant activity at low concentrations, with an effective dose significantly lower than thrombin. The protein's targeting capability also effectively improves the therapeutic safety window, demonstrating high clinical application value.
[0120] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.
Claims
1. A fusion protein for promoting blood clotting, characterized in that, The fusion protein comprises the following components: (i) the extracellular domain of tissue factor protein, (ii) an anti-TLT-1 single-domain antibody, and (iii) a linker peptide; the number of the anti-TLT-1 single-domain antibody is one or more; the anti-TLT-1 single-domain antibody is located at the N-terminus or C-terminus of the extracellular domain of the tissue factor; the linker peptide is used for linking (i) and (ii).
2. The fusion protein according to claim 1, characterized in that, The extracellular domain of the tissue factor protein has the amino acid sequence shown in SEQ ID NO.2; the anti-TLT-1 single-domain antibody includes any one of the amino acid sequences shown in SEQ ID NO.3-5, or an amino acid sequence having at least 95% homology with the framework region of the nanobody shown in any one of the amino acid sequences shown in SEQ ID NO.3-5.
3. The fusion protein according to claim 1, characterized in that, The linker peptide is 15-30 amino acids in length, and the amino acid sequence of the linker peptide includes the amino acid sequence shown in SEQ ID NO. 6 or 7.
4. The fusion protein according to claim 1, characterized in that, The structure of the fusion protein is selected from any combination of the following: Combination 1: (i)-(iii)-(ii)-(iii)-(ii); Combination 2: (ii)-(iii)-(ii)-(iii)-(i); Combination 3: (ii)-(iii)-(i).
5. The fusion protein according to claim 4, characterized in that, When the fusion protein structure is selected from combination 1, it includes the amino acid sequence shown in any one of SEQ ID NO. 25, 30, 32 and 33; when the fusion protein structure is selected from combination 2, it includes the amino acid sequence shown in any one of SEQ ID NO. 26, 28, 31, 34 and 35; when the fusion protein structure is selected from combination 3, it includes the amino acid sequence shown in SEQ ID NO.
38.
6. The fusion protein according to any one of claims 1-5, characterized in that, The fusion protein also has a histidine tag attached to its C-terminus.
7. A genetically engineered product, characterized in that, Choose from any one or more of the following: 1) A nucleic acid encoding the fusion protein according to any one of claims 1-6; 2) An expression vector, wherein the expression vector comprises the nucleic acid described in 1); 3) A genetically engineered cell, wherein the genetically engineered cell contains the nucleic acid described in 1), the expression vector described in 2), or expresses the fusion protein described in any one of claims 1-6, and the genetically engineered cell includes prokaryotic cells or eukaryotic cells.
8. The use of the fusion protein according to any one of claims 1-6 or the genetically engineered product according to claim 7 in the preparation of hemostatic products for trauma or perioperative period.
9. A product for hemostasis in the context of trauma or perioperative period, characterized in that, Choose from any one or more of the following: A. The product comprises the fusion protein according to any one of claims 1-6; B. The product is prepared using the genetically engineered product described in claim 7.
10. The product according to claim 9, characterized in that, The product is a pharmaceutical composition comprising a pharmaceutically acceptable formulation and pharmaceutical excipients, wherein the pharmaceutical excipients are selected from any one or more of topical sprays, syringes, creams, and gelatin sponges; and the product is selected from any one of solutions, suspensions, powders, and gels.
